Identification and use of treatment (tx) options in patients (pts) with advanced non-small cell lung cancer (aNSCLC) after comprehensive genomic profiling (CGP): A real-world study.

被引：0
|
作者：
Mascaux, Celine
Bubendorf, Lukas
Barlesi, Fabrice
Clendening, James W.
Zhang, Qing
Mace, Kieran
Gondos, Adam
Foser, Stefan
Wang, Lisa I.
Paz-Ares, Luis G.
机构：
[1] Aix Marseille Univ, CNRS, INSERM, CRCM,APHM, Marseille, France
[2] Univ Hosp Basel, Basel, Switzerland
[3] F Hoffmann La Roche Ltd, Mississauga, ON, Canada
[4] Genentech Inc, San Francisco, CA 94080 USA
[5] F Hoffmann La Roche Ltd, Basel, Switzerland
[6] Hosp Univ Doce Octubre, Dept Med Oncol, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9076
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Comprehensive genomic profiling (CGP) and PD-L1 IHC in patients (pts) with advanced non-small cell lung cancer (aNSCLC): Testing and treatment (Tx) patterns in the real-world (RW) setting
    VanderWalde, A. M.
    Lee, J.
    Tolba, K.
    Ward, A.
    Cooper, M.
    Huang, R. S. P.
    Venstrom, J.
    Oxnard, G.
    Schrock, A. B.
    Schwartzberg, L.
    ANNALS OF ONCOLOGY, 2021, 32 : S1006 - S1007
  • [2] Actionability of comprehensive genomic profiling (CGP) compared to single-gene and small panels in patients with advanced/metastatic non-small cell lung cancer (aNSCLC): A real-world study.
    Bapat, Bela
    Sweetnam, Connor
    McBratney, Ashleigh
    Izano, Monika A.
    Schroeder, Brock
    Walters, Sheetal
    Chen, William
    Febbo, Phillip G.
    Berry, Anna B.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] Comprehensive genomic profiling (CGP) changes management and improves survival in patients with advanced non-small cell lung cancer (aNSCLC)
    Simon, G.
    Berry, A.
    Bapat, B.
    Law, J.
    Sweetnam, C.
    Mohammed, H.
    McBratney, A.
    Izano, M.
    Bryan, M. Scannell
    Spencer, S.
    Hostin, D.
    Schroeder, B.
    Febbo, P. G.
    ANNALS OF ONCOLOGY, 2023, 34
  • [4] Analysis of real-world data (RWD) on treatment (tx) sequencing in patients with advanced non-small cell lung cancer (aNSCLC).
    Ma, Meng
    Zhou, Xiang
    Goldsweig, Howard
    Hahner, Nicholas
    Han, Dianwei
    Dietz, Matthew
    Jones, Scott
    Mullaney, Tommy
    Redfern, Arielle
    Jappe, Whitney
    Liu, Zongzhi
    Yadav, Kamlesh
    Zimmerman, Michelle
    Prentice, Tony
    Pan, Qi
    Hirsch, Fred R.
    Oh, William K.
    Schadt, Eric E.
    Li, Dan
    Chen, Rong
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Real-world treatment sequencing in advanced non-small cell lung cancer (aNSCLC).
    Radtchenko, Janna
    Feinberg, Bruce A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] Real-World Clinical Outcomes in Patients with Advanced Non-Small Cell Lung Cancer (aNSCLC) in the US
    Nadler, E.
    Chang, J.
    Zhang, X.
    Aguilar, K.
    Zhou, J.
    Arondekar, B.
    Pawar, V.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S38 - S39
  • [7] Real-world characterization of advanced/metastatic non-small cell lung cancer (aNSCLC) patients (pts) with rapid disease progression (RDP).
    Gutierrez, Martin
    Molife, Cliff
    Belli, Andrew J.
    Hansen, Eric
    Stefaniak, Victoria Jennifer
    Winfree, Katherine B.
    Cui, Zhanglin Lin
    Batus, Marta
    Clarke, Jeffrey Melson
    Narayanan, Viraj
    Manion, Chelsea
    Norden, Andrew David
    Bonomi, Philip D.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Treatment Patterns and Survival of Patients With Advanced Non-Small Cell Lung Cancer Guided by Comprehensive Genomic Profiling: Real-World Single-Institute Study in China
    Lv, Weize
    Cheng, Hua
    Shao, Di
    Wei, Yajun
    Zhu, Weiping
    Wu, Kui
    Jiang, Wenxi
    Hu, Liyang
    Sha, Zhou
    Zhong, Beilong
    Pei, Xiaofeng
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [9] Immune-related adverse events (irAEs) in advanced non-small cell lung cancer (aNSCLC) patients (pts): A real-world analysis
    Pretelli, G.
    Pavan, A.
    Dal Maso, A.
    Resi, M. V.
    Mulargiu, C.
    Ferro, A.
    Benetti, B.
    Lorenzi, M.
    Marinato, G. M.
    Frega, S.
    Pasello, G.
    Conte, P. F.
    Guarneri, V.
    Bonanno, L.
    ANNALS OF ONCOLOGY, 2022, 33 : S51 - S51
  • [10] Real-world economic burden of rapid disease progression (RDP) in patients (pts) with advanced/metastatic non-small cell lung cancer (aNSCLC).
    Byfield, Stacey DaCosta
    Molife, Cliff
    Batus, Marta
    Winfree, Katherine B.
    White, John C.
    Cui, Zhanglin Lin
    Lal, Lincy S.
    Stefaniak, Victoria Jennifer
    Bonomi, Philip D.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345